SELLAS Life Sciences Group, Inc. Share Price

Equities

SLS

US81642T2096

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 21/06/2024 BST 5-day change 1st Jan Change
1.22 USD +5.17% Intraday chart for SELLAS Life Sciences Group, Inc. -18.67% +15.09%
Sales 2024 * - Sales 2025 * - Capitalization 70.46M 5.56B
Net income 2024 * -37M -2.92B Net income 2025 * -38M -3B EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-1.75 x
P/E ratio 2025 *
-2 x
Employees 16
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.73%
More Fundamentals * Assessed data
Dynamic Chart
SELLAS Life Sciences Group, Inc. Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia CI
SELLAS Life Sciences Group, Inc. Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML CI
Certain Common Stock of SELLAS Life Sciences Group, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024. CI
SELLAS Life Sciences Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
SELLAS Life Sciences Group, Inc. Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level CI
SELLAS Life Sciences Group, Inc. Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study CI
North American Morning Briefing : Powell Awaited -2- DJ
SELLAS Life Sciences Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : SELLAS Life Sciences Group, Inc. - Special Call
SELLAS Life Sciences Group, Inc. Announces Positive Topline Data from the Phase 2a Study of Sls009 in r/r AML CI
Sector Update: Health Care Stocks Ease Late Afternoon MT
Top Midday Decliners MT
Sector Update: Health Care Stocks Softer Friday Afternoon MT
Sellas Life Sciences Launches $20 Million Direct Offering, Private Placement -- Shares Fall MT
SELLAS Life Sciences Group, Inc. announced a financing transaction CI
More news

Latest transcript on SELLAS Life Sciences Group, Inc.

1 day+5.17%
1 week-18.67%
Current month-13.48%
1 month-9.63%
3 months+14.02%
6 months+19.61%
Current year+15.09%
More quotes
1 week
1.05
Extreme 1.05
1.30
1 month
0.81
Extreme 0.81
1.70
Current year
0.50
Extreme 0.4986
1.72
1 year
0.50
Extreme 0.4986
1.91
3 years
0.50
Extreme 0.4986
15.08
5 years
0.50
Extreme 0.4986
19.38
10 years
0.50
Extreme 0.4986
554.50
More quotes
Managers TitleAgeSince
Founder 48 02/04/06
Director of Finance/CFO 39 30/04/13
General Counsel - 04/01/23
Members of the board TitleAgeSince
Director/Board Member 67 28/12/17
Director/Board Member 68 30/11/17
Director/Board Member 64 28/12/17
More insiders
Date Price Change Volume
21/06/24 1.22 +5.17% 1,648,455
20/06/24 1.16 +9.43% 1,551,214
18/06/24 1.06 -15.20% 2,595,612
17/06/24 1.25 -16.67% 6,171,965

Delayed Quote Nasdaq, June 21, 2024 at 09:00 pm

More quotes
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of novel therapeutics for a range of cancer indications. The Company's product candidates, galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9), inhibitor. GPS is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.22 USD
Average target price
5.833 USD
Spread / Average Target
+378.14%
Consensus